It is a major: B-lymphocyte marker, carried by benign cells as well as malgnant cells with b-cell lineage (as opposed to t-cell lineage). The ab Rituximab has been generated against it and is a key component in treating b-cell lymphomas.
Answered 7/1/2014
5.7k views
Yes: Most of your normal b-cells bear this marker. It's typically used in subclassifying malignant lymphomas that have already been diagnosed, in combination with a huge array of other markers, though it can be used to "light up" the distribution of b-cells in non-cancerous tissue as well. It's the target for Rituximab and some other new rx's.
Answered 7/1/2014
5.7k views
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
A doctor has provided 1 answer
6 doctors weighed in across 2 answers
90,000 U.S. doctors in 147 specialties are here to answer your questions or offer you advice, prescriptions, and more.
Ask your question